^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NT-175

    i
    Associations
    News

    Trials

    Company:
    AstraZeneca
    Drug class:
    TCR modulator, P53 expression modulator
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation (NT-175-201) (NCT05877599)
    Phase 1
    AstraZeneca
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    07/12/2023
    Primary completion :
    09/01/2028
    Completion :
    08/01/2039
    TP53 • HLA-A
    |
    TP53 mutation • HLA-A*02:01
    |
    cyclophosphamide • fludarabine IV • NT-175